ObsEva logo

ObsEva(OTC) OBSV

Market CapN/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2017)-100%
5 Year-100%
1 Year-99%
1 Month-99%
N/A
ObsEva last closing stock price
MetricPriceDate
Last closeUSD 0.002026-10-12
ObsEva stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-99%USD 0.002026-10-05
1 month-99%USD 0.002026-09-11
3 month-99%USD 0.002026-07-14
Year to date-99%USD 0.002025-12-31
1 year-99%USD 0.002025-10-09
3 year-100%USD 0.062023-10-13
5 year-100%USD 2.802021-10-13
Since inception-100%USD 11.652017-01-26

ObsEva Financials at a Glance

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$19.64M

Net Income (TTM)

-$29.88M

EPS (TTM)

N/A

P/E Ratio

N/A

Dividend

N/A

Beta (Volatility)

N/A

Price

N/A

Volume

N/A

Open

N/A

Previous Close

N/A

Daily Range

N/A

52-Week Range

N/A

Estimated Earnings Date

Aug 15, 2023

OBSV News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About ObsEva

ObsEva S.A. is a biopharmaceutical firm focused on developing innovative treatments for women's reproductive health and pregnancy. The company is advancing several key products through clinical trials, aiming to address significant unmet medical needs in this sector.

Products and Services
  • Linzagolix: An oral GnRH receptor antagonist in Phase III trials for endometriosis and uterine fibroids
  • Ebopiprant: A selective oral PGF2a receptor antagonist in Phase II trials for preterm labor
  • Nolasiban: An oral oxytocin receptor antagonist in Phase I development for IVF outcomes
Growth Outlook
  • Strong pipeline with multiple products in advanced clinical stages
  • Potential market expansion as women's health awareness increases
  • Strategic partnerships may enhance development and commercialization efforts
Financial Highlights
  • Recent quarterly revenue of $19.6 million, a significant increase from previous quarters
  • Cash and cash equivalents of $14.9 million as of Q4 2022, supporting ongoing operations
  • Operating income of $5.2 million in Q4 2022, indicating improved financial performance
ObsEva S.A. operates in a vital sector with a focus on women's health, an area that has historically been underfunded and underserved. The company's innovative pipeline, including Linzagolix and Ebopiprant, addresses critical health issues such as endometriosis and preterm labor, which affect millions of women globally. The recent financial performance shows promising growth, with a notable increase in revenue and operating income, reflecting the company's potential for future success. With a solid cash position, ObsEva is well-positioned to continue its development efforts and capitalize on market opportunities in women's reproductive health.
AI Generated • Sep 25, 2026

Industry

Biotechnology

Sector

Health Care

Employees

15

CEO

Brian O'Callaghan, MBA

Website

www.obseva.com

Headquarters

Geneva, 1228, CH

OBSV Financials

Key Financial Metrics (TTM)

Gross Margin

100.00%

Operating Margin

-79.83%

Net Income Margin

-152.16%

Return on Equity

-146.39%

Return on Capital

-136.20%

Return on Assets

-180.60%

Earnings Yield

N/A

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

N/A

Volume

N/A

Avg. Volume

N/A

Financials (TTM)

Gross Profit

$19.64M

Operating Income

-$34.58M

EBITDA

-$5.74M

Operating Cash Flow

-$23.15M

Capital Expenditure

$0.00

Free Cash Flow

-$23.15M

Cash & ST Invst.

$8.42M

Total Debt

$3.03M

ObsEva Performance Analysis

ObsEva annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20212021-12-31USD 22,200,000N/A
20222022-12-31USD 19,637,000-11.5%
ObsEva sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q12022-03-31N/A
Q22022-06-30N/A
Q32022-09-30N/A
Q42022-12-31N/A
ObsEva annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20212021-12-31USD -0.70N/A
20222022-12-31USD -0.32-53.9%
ObsEva sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q12022-03-3146.2%
Q22022-06-30-178.6%
Q32022-09-3066.7%
Q42022-12-31323.1%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q4 2022YOY CHG

Revenue

$19.64M

N/A

Gross Profit

$19.64M

N/A

Gross Margin

100.00%

N/A

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

N/A

N/A

Employees

48

N/A

Net Income

$26.78M

+233.6%

EBITDA

$31.72M

+186.4%

Quarterly Fundamentals

Name
Q4 2022YOY CHG

Total Cash

$8.42M

-84.6%

Total Debt

$3.03M

-88.6%

Accounts Receivable

$252.00K

-92.9%

Inventory

$0.00

N/A

Long Term Debt

$0.00

-100.0%

Short Term Debt

$3.03M

+341.3%

Return on Assets

-1.81%

N/A

Return on Invested Capital

-1.68%

N/A

Free Cash Flow

$7.94M

+162.3%

Operating Cash Flow

$7.92M

+162.1%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
AMTIApplied Molecular Transport Inc.
$0.26-3.13%
KRROKorro Bio, Inc.
$8.81-5.98%
CYCCCyclacel Pharmaceuticals, Inc.
$6.37-5.98%
IMVIFIMV Inc.
$0.00+0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
SOXSDirexion Shares ETF Trust - Direxion Daily Semiconductor Bear 3x ETF
$37.42+0.62%
KORUDirexion Shares ETF Trust - Direxion Daily Msci South Korea Bull 3x Shares
$14.72-6.48%
SOXLDirexion Shares ETF Trust - Direxion Daily Semiconductor Bull 3x ETF
$127.57-0.65%
NOKNokia
$9.86-0.40%

Questions About OBSV

What is the current price of ObsEva?

ObsEva is trading at N/A per share.

What is the 52-week range for ObsEva?

Over the past 52 weeks, ObsEva has traded between N/A and N/A.

How much debt does ObsEva have?

As of the most recent reporting period, ObsEva reported total debt of $3.03M.

How much cash does ObsEva have on hand?

ObsEva reported $14.96M in cash and cash equivalents in its most recent financial results.

What is ObsEva’s dividend yield?

ObsEva does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services